-
Long-overdue conclusion to the UK Infected Blood Inquiry Lancet HIV (IF 12.8) Pub Date : 2024-06-13 The Lancet HIV
-
UK Infected Blood Inquiry highlights decades of failings Lancet HIV (IF 12.8) Pub Date : 2024-06-07 Talha Burki
-
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa Lancet HIV (IF 12.8) Pub Date : 2024-06-06 Diego F Cuadros PhD, Qian Huang PhD, Godfrey Musuka PhD, Tafadzwa Dzinamarira PhD, Brian K Moyo PhD, Amon Mpofu PhD, Tatenda Makoni PhD, Prof F DeWolfe Miller PhD, Anna Bershteyn PhD
The HIV epidemic in sub-Saharan Africa displays a varied geographical distribution, with particular regions termed as HIV hotspots due to a higher prevalence of infection. Addressing these hotspots is essential for controlling the epidemic. However, these regions, influenced by historical factors, challenge standard interventions. Legacy effects—the lasting impact of past events—play a substantial
-
Reducing HIV transmission in British Columbia, Canada Lancet HIV (IF 12.8) Pub Date : 2024-06-04 Ann Duerr, Chris Beyrer
-
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation Lancet HIV (IF 12.8) Pub Date : 2024-06-04 Viviane D Lima PhD, Jielin Zhu PhD, Rolando Barrios MD, Junine Toy PharmD, Jeffrey B Joy PhD, Brian G Williams PhD, Reuben Granich MD, Zunyou Wu MD, Jason Wong MD, Prof Julio S G Montaner MD
Treatment as prevention and pre-exposure prophylaxis (PrEP) are key strategies in the control of HIV/AIDS. We aimed to characterise the longitudinal effects of antiretroviral therapy (ART), followed by treatment as prevention and the addition of PrEP, on the HIV effective reproduction number (R) in British Columbia, Canada. This population-level programme evaluation used data from the Drug Treatment
-
Reducing time to viral suppression in Europe Lancet HIV (IF 12.8) Pub Date : 2024-05-30 Lise Cuzin, Pascal Pugliese
-
Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study Lancet HIV (IF 12.8) Pub Date : 2024-05-30 Alejandro G García-Ruiz de Morales MD, María Jesús Vivancos PhD, María de Lagarde PhD, Margarita Ramírez Schacke MD, Maria del Mar Arcos Rueda MD, Eva Orviz MD, Adrian Curran PhD, Francisco Carmona-Torre MD, Prof Santiago Moreno PhD, María Jesús Pérez-Elías PhD, Javier Martínez-Sanz PhD, Cohort of the Spanish HIV/AIDS Research Network
Ending AIDS by 2030 requires improvements across all stages of the HIV care continuum. We used a longitudinal approach to assess changes in the HIV care continuum in Spain and transition probabilities across different stages. We used data from the prospective Cohort of the Spanish HIV/AIDS Research Network to analyse the time from diagnosis to linkage to care, linkage to care to antiretroviral therapy
-
Second-line HIV treatments for adults in LMICs Lancet HIV (IF 12.8) Pub Date : 2024-05-21 Esaú C João
-
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial Lancet HIV (IF 12.8) Pub Date : 2024-05-21 D2EFT Study Group, Gail Matthews, Simone Jacoby, Margaret Borok, Nnakelu Eriobu, Richard Kaplan, Nagalingeswaran Kumarasamy, Jaclyn Ann Bennet, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Sandra Wagner Cardoso, Iskandar Azwa, Marcelo Losso, Dannae Brown, Dona Arlinda, Jolie Hutchinson, Anthony Kelleher, Mohamed Cisse, Sounkalo Dao, Mark Polizzotto, Sean Emery, Matthew Law, Emmanuelle Papot, Muhammad
-
Closing the equity gap in the treatment of HIV-2 infection Lancet HIV (IF 12.8) Pub Date : 2024-05-10 Sarah Rowland-Jones, Ester Gea-Mallorquí
-
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial Lancet HIV (IF 12.8) Pub Date : 2024-05-10 Serge P Eholie MD, Didier K Ekouevi PhD, Corine Chazallon MSc, Charlotte Charpentier PhD, Eugène Messou PhD, Zelica Diallo MPH, Jacques Zoungrana MD, Albert Minga MPH, Ndeye Fatou Ngom Gueye MD, Denise Hawerlander MD, Fassery Dembele MD, Géraldine Colin MPH, Boris Tchounga PhD, Sophie Karcher MSc, Jérome Le Carrou PhD, Annick Tchabert-Guié MD PhD, Thomas-d'Aquin Toni PhD, Abdoul-Salam Ouédraogo PhD
Due to the low number of individuals with HIV-2, no randomised trials of HIV-2 treatment have ever been done. We hypothesised that a non-comparative study describing the outcomes of several antiretroviral therapy (ART) regimens in parallel groups would improve understanding of how differences between HIV-1 and HIV-2 might lead to different therapeutic approaches. This pilot, phase 2, non-comparative
-
Is this the end of the road for daily islatravir 0·75 mg? Lancet HIV (IF 12.8) Pub Date : 2024-05-08 Jennifer Hoy, James McMahon
-
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial Lancet HIV (IF 12.8) Pub Date : 2024-05-08 Prof Jean-Michel Molina MD, Giuliano Rizzardini MD, Prof Catherine Orrell MD, Alejandro Afani MD, Prof Alexandra Calmy MD, Shinichi Oka MD, Federico Hinestrosa MD, Prof Princy Kumar MD, Prof Pablo Tebas MD, Prof Sharon Walmsley MD, Anjana Grandhi PhD, Stephanie Klopfer PhD, Isaias Gendrano PhD, Karen Eves BS, Todd A Correll PharmD, Michelle C Fox MD, Jason Kim MD
Doravirine and islatravir is an investigational, once-daily, single-tablet regimen with high antiviral potency, favourable safety and tolerability, and low propensity for resistance. We report week 48 results from a phase 3 trial evaluating switch from stable, oral antiretroviral therapy (ART) to the fixed combination of doravirine (100 mg) and islatravir (0·75 mg). This phase 3, multicentre, randomised
-
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial Lancet HIV (IF 12.8) Pub Date : 2024-05-08 Anthony M Mills MD, Giuliano Rizzardini MD, Prof Moti N Ramgopal MD, Olayemi O Osiyemi MD, Johannes R Bogner MD, Debbie P Hagins MD, Roger Paredes PhD, Prof Jacques Reynes MD, Prof Jürgen K Rockstroh MD, Prof Andrew Carr DSc, Feng-Hsiu Su MBA, Stephanie O Klopfer PhD, Karen Eves BS, Rebeca M Plank MD, Todd Correll PharmD, Michelle C Fox MD
Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance. We investigated a switch from bictegravir, emtricitabine, and tenofovir alafenamide to doravirine (100 mg) and islatravir (0·75 mg) in virologically suppressed adults with HIV-1. We conducted a phase 3, multicentre, randomised, active-controlled
-
Context-specific estimates of vertical transmission Lancet HIV (IF 12.8) Pub Date : 2024-04-30 Souleymane Tassembedo, Isidore Tiandiogo Traore, Abdoul-Salam Ouedraogo, Nicolas Meda, Philippe Van de Perre, Nicolas Nagot, Fati Kirakoya-Samadoulougou
-
Two-drug regimens for the treatment of HIV in Africa Lancet HIV (IF 12.8) Pub Date : 2024-04-30 Ivan Mambule MBChB, Claire Norcross, Loice Achieng Ombajo MMed, Simiso Sokhela MBChB, Eva Agnes Laker Odongpiny MSc, Noela Owarwo MMed, David S Lawrence PhD, Eugene Ruzagira PhD, Fiona V Cresswell PhD
Two-drug regimens for the treatment of HIV are increasingly available. The oral regimen of dolutegravir plus lamivudine is recommended as a preferred option in multiple national guidelines but is not currently included in WHO HIV treatment guidelines nor widely used in Africa. Long-acting injectable cabotegravir and rilpivirine is being rolled out in the USA, Europe, and Australia but its use in sub-Saharan
-
-
Another crackdown on LGBTQ+ people in Africa Lancet HIV (IF 12.8) Pub Date : 2024-04-29 The Lancet HIV
-
DNA and protein HIV vaccines: how should we mix it? Lancet HIV (IF 12.8) Pub Date : 2024-04-29 Yves Levy
-
HIV at a crossroads in Pakistan Lancet HIV (IF 12.8) Pub Date : 2024-04-29 Hussain A Raza, Mohummad H R Raja, Muhammad M Khakwani, Bushra Jamil
-
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial Lancet HIV (IF 12.8) Pub Date : 2024-04-29 Ian Frank MD, Shuying S Li PhD, Nicole Grunenberg MD, Edgar T Overton MD, Samuel T Robinson PhD, Hua Zheng MS, Kelly E Seaton PhD, Jack R Heptinstall MS, Mary A Allen MS, Kenneth H Mayer MD, Daniel A Culver DO, Michael C Keefer MD, Sri Edupuganti MD, Michael N Pensiero PhD, Vijay L Mehra PhD, Stephen C De Rosa MD, Daryl E Morris MS, Shixia Wang PhD, Michael S Seaman PhD, David C Montefiori PhD, Guido
An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate safety and immunogenicity of a unique polyvalent DNA–protein HIV vaccine with matching envelope (Env) immunogens. HVTN 124 was a randomised, phase 1, placebo-controlled, double-blind study, including participants who were
-
More pressure on integrase strand-transfer inhibitors? Lancet HIV (IF 12.8) Pub Date : 2024-04-12 Anton L Pozniak, W D Francois Venter
-
Expanding options of child-friendly, single-tablet regimens for young children with HIV Lancet HIV (IF 12.8) Pub Date : 2024-04-12 Tim R Cressey, Anna Turkova
-
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts Lancet HIV (IF 12.8) Pub Date : 2024-04-12 Dathan M Byonanebye PhD, Prof Mark N Polizzotto PhD, Fernando Maltez PhD, Andri Rauch PhD, Katharina Grabmeier-Pfistershammer MD, Ferdinand Wit PhD, Prof Stéphane De Wit PhD, Prof Antonella Castagna MD, Prof Antonella d'Arminio Monforte MD, Prof Cristina Mussini MD, Jan-Christian Wasmuth MD, Eric Fontas PhD, Irene Abela PhD, Mario Sarcletti MD, Loveleen Bansi-Matharu PhD, Nadine Jaschinski MD, Lars
Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts. However, whether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk of weight-related clinical events is unclear. We aimed to assess whether changes in BMI differentially increase hypertension or dyslipidaemia
-
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study Lancet HIV (IF 12.8) Pub Date : 2024-04-12 Prof Carina A Rodriguez MD, Eva Natukunda MD, Renate Strehlau MD, Esme L Venter MBChB, Supattra Rungmaitree MD, Prof Coleen K Cunningham MD, Prof Umesh Lalloo MBChB, Prof Pope Kosalaraksa MD, Elizabeth HellstrÖm MD, Afaaf Liberty MD, Eric J McGrath MD, Meenu Kaur MSc, Rory Leisegang PhD, Jason T Hindman Pharm D, Vinicius A Vieira MD, Kathryn Kersey MSc, Prof Mark F Cotton MD, Prof Natella Rakhmanina
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to <18 years) in a 48-week phase 2/3 trial. In this study, we report data from children aged at least 2 years and weighing 14 kg to less than 25 kg. We conducted this open-label, multicentre, multicohort, single-arm study
-
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians Lancet HIV (IF 12.8) Pub Date : 2024-04-08 Andrés Esteban-Cantos PhD, Rocío Montejano PhD, Adriana Pinto-Martínez MD, Javier Rodríguez-Centeno PhD, Federico Pulido PhD, Prof José R Arribas PhD
In individuals receiving antiretroviral therapy (ART), persistent low-level viraemia not attributed to suboptimal ART adherence, detrimental pharmacological interactions, or drug resistance is referred to as non-suppressible viraemia (NSV). This Review presents recent findings in the virological characterisation of NSV, revealing that it consists of one or a few identical populations of plasma viruses
-
Enhancing HIV care with incentives: one size does not fit all Lancet HIV (IF 12.8) Pub Date : 2024-04-04 Sandra I McCoy, Amon Sabasaba
-
Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial Lancet HIV (IF 12.8) Pub Date : 2024-04-04 Prof Sunil S Solomon MBBS, Allison M McFall PhD, Aylur K Srikrishnan BA, Vinita Verma M Phil, Santhanam Anand BSc, Rifa T Khan MScPH, Bhawani Singh Kushwaha MD, Canjeevaram Vasudevan BA, Shanmugam Saravanan PhD, Nandagopal Paneerselvam PhD, Muniratnam Suresh Kumar MD, Chinmoyee Das DNB, Prof David D Celentano ScD, Prof Shruti H Mehta PhD, Prof Gregory M Lucas MD
Progress on HIV treatment outcomes for people who inject drugs and men who have sex with men in India has been slow compared with that in other populations. We assessed whether HIV treatment incentives would improve outcomes among these groups. We did a matched-pair, cluster randomised trial in 16 sites (eight for people who inject drugs and eight for men who have sex with men) across 15 cities in
-
Intersectional climate justice, health equity, and HIV Lancet HIV (IF 12.8) Pub Date : 2024-04-03 Sarah M Wilson, Griffin Woolley, Chris Hawn, Kate Hoffman, Akhenaton-Andrew D Jones, Cliburn Chan, Sarah V Mudrak, M Umar Qureshi, Ashley Ward, Elizabeth T Knippler, N Lance Okeke, Amy Corneli, Georgia D Tomaras, R Keith Reeves
-
-
Collective antiretroviral protection: new dimensions of community HIV prevention practices at the intersection of U=U and PrEP Lancet HIV (IF 12.8) Pub Date : 2024-03-18 Julien B Brisson PhD, Daniel Grace PhD, Amaya G Perez-Brumer PhD
Collective antiretroviral protection is an evolving sexual health strategy in HIV prevention, used in particular by gay, bisexual, and other men who have sex with men. The strategy involves HIV-negative individuals who engage in condomless sexual activities but, instead of using pre-exposure prophylaxis (PrEP) themselves, choose partners who either have undetectable viral loads or are on PrEP. This
-
-
-
Evidence with 95-95-95 that ambitious is feasible Lancet HIV (IF 12.8) Pub Date : 2024-03-08 Mathieu Maheu-Giroux, Sharmistha Mishra
-
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey Lancet HIV (IF 12.8) Pub Date : 2024-03-08 Madisa Mine PhD, Kristen A Stafford PhD, Rebecca L Laws PhD, Reson Marima MD, Phenyo Lekone PhD, Dinah Ramaabya BNSc, Kgomotso Makhaola PhD, Hetal K Patel MS, Prichard Mapondera MSc, Floris Wray-Gordon PhD, Chinedu Agbakwuru MD, Lillian Okui MBBS, Susan Matroos BA, Eden Onyadile MSc, Julia Ngidi BSc, Prof Alash'le Abimiku PhD, Khuteletso Bagapi MPH, Bornapate Nkomo MD, Stephane M Bodika MD, Kaylee
In 2014, UNAIDS set a goal to end the AIDS epidemic by achieving targets for the percentage of people living with HIV who were aware of their status, on antiretroviral therapy (ART), and virally suppressed. In 2020, these targets were revised to 95% for each measure (known as 95-95-95), to be reached among people living with HIV by 2025. We used data from the Fifth Botswana AIDS Impact Survey (BAIS
-
Low-cost urine tenofovir assay to triage dolutegravir resistance testing Lancet HIV (IF 12.8) Pub Date : 2024-03-07 Tyler Martinson, Jacinta Nwogu-Attah, Matthew Spinelli, Monica Gandhi
-
Uncovering HIV and malaria interactions: the latest evidence and knowledge gaps Lancet HIV (IF 12.8) Pub Date : 2024-03-05 Antía Figueroa-Romero MSc, Anna Saura-Lázaro MD, Sheila Fernández-Luis PhD, Raquel González PhD
The geographical distribution of malaria and HIV infections widely overlap in sub-Saharan Africa, constituting a complex global health challenge. The interplay between both infections raises concerns about potential immunological, clinical, and therapeutic interactions. Both diseases have been reported to exacerbate the transmission of the other, including the possible vertical transmission of HIV
-
Health equity for Black sexually minoritised men through status-neutral HIV care Lancet HIV (IF 12.8) Pub Date : 2024-02-28 Jade Pagkas-Bather MD, Darnell N Motley PhD, Prof John A Schneider MD
Current strategies (both biomedical and barrier methods) for HIV elimination in the USA do not best serve those who are most affected by HIV. Improving healthc are for individuals most affected by HIV requires restructuring of care delivery to improve their HIV outcomes. The transformation of clinical care delivery is crucial to address the needs of one of the most affected populations along the HIV
-
Who benefits from frequent asymptomatic STI screening? Lancet HIV (IF 12.8) Pub Date : 2024-02-26 Nicholas Medland, Rebecca Guy
-
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial Lancet HIV (IF 12.8) Pub Date : 2024-02-26 Thibaut Vanbaelen PhD, Achilleas Tsoumanis PhD, Eric Florence PhD, Christophe Van Dijck PhD, Diana Huis in 't Veld PhD, Anne-Sophie Sauvage MD, Natacha Herssens MSc, Irith De Baetselier PhD, Anke Rotsaert MSc, Prof Veronique Verhoeven PhD, Sophie Henrard MD, Yven Van Herrewege PhD, Dorien Van den Bossche PhD, Prof Jean-Christophe Goffard PhD, Elizaveta Padalko PhD, Thijs Reyniers PhD, Bea Vuylsteke
Guidelines recommend screening for and at three anatomical sites (urethra, anus, and pharynx) every 3 months (3 × 3) in men who have sex with men (MSM) and transgender women taking HIV pre-exposure prophylaxis (PrEP). We present the first randomised controlled trial to compare the effect of screening versus non-screening for and on the incidence of these infections in MSM and transgender women taking
-
Response to Thailand's commitment to support community-led HIV services Lancet HIV (IF 12.8) Pub Date : 2024-02-06 Nittaya Phanuphak, Surang Janyam, Pongpeera Patpeerapong, Satayu Sittikan, Kittinan Daramadhaj, Supabhorn Pengnonyang, Rena Janamnuaysook, Inthira Suya, Stephen Mills, Praphan Phanuphak
-
Thailand's commitment to support community-led HIV services Lancet HIV (IF 12.8) Pub Date : 2024-02-06 Cheewanan Lertpiriyasuwat, Suchada Jiamsiri, Plearnpit Prommali
-
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study Lancet HIV (IF 12.8) Pub Date : 2024-01-30 Joseph J Eron, Susan J Little, Gordon Crofoot, Paul Cook, Peter J Ruane, Dushyantha Jayaweera, Laurie A VanderVeen, Edwin DeJesus, Yanan Zheng, Anthony Mills, Hailin Huang, Sarah E Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M Baeten, Marina Caskey
Background Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits. We evaluated treatment with two antibodies that broadly and potently neutralise HIV (broadly neutralising antibodies; bNAbs), combined with lenacapavir, a long-acting capsid inhibitor, as a long-acting regimen. Methods This ongoing
-
Lenacapavir plus two bNAbs: feasible, with some caveats Lancet HIV (IF 12.8) Pub Date : 2024-01-30 Esteban Martinez
Abstract not available
-
HIV self-testing, PrEP, and drug resistance: some insights Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Walter Ochieng, Chutima Suraratdecha
Abstract not available
-
Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Sarah N Cox, Linxuan Wu, Rachel Wittenauer, Samantha Clark, D Allen Roberts, Ifechukwu Benedict Nwogu, Olga Vitruk, Alexandra P Kuo, Cheryl Johnson, Muhammad S Jamil, Anita Sands, Robin Schaefer, Christine Kisia, Rachel Baggaley, Joanne D Stekler, Adam Akullian, Monisha Sharma
Background Community-based oral pre-exposure prophylaxis (PrEP) provision has the potential to expand PrEP coverage. HIV self-testing can facilitate PrEP community-based delivery but might have lower sensitivity than facility-based HIV testing, potentially leading to inappropriate PrEP use among people with HIV and subsequent development of drug resistance. We aimed to evaluate the impact of HIV self-testing
-
Disparities in approaches to ART access in Europe Lancet HIV (IF 12.8) Pub Date : 2024-02-02 Laure Tribaudeau, Frédéric Eyvrard
Abstract not available
-
Call for justice-informed HIV cure trials with ATIs Lancet HIV (IF 12.8) Pub Date : 2024-01-25 Karine Dubé, Amaya Perez-Brumer
Abstract not available
-
Effect of climate change on the HIV response Lancet HIV (IF 12.8) Pub Date : 2024-01-29 The Lancet HIV
Abstract not available
-
A call to accelerate antiretroviral development for neonates Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Aditya H Gaur, George K Siberry
Abstract not available
-
Insights on COVID-19 mortality and HIV from South Africa Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Jessica E Justman, Tara F Abularrage
Abstract not available
-
Thank you to The Lancet HIV's statistical and peer reviewers in 2023 Lancet HIV (IF 12.8) Pub Date : 2024-01-29 The Lancet HIV Editors
Abstract not available
-
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Prof Adrie Bekker PhD, Nicolas Salvadori PhD, Prof Helena Rabie PhD, Samantha du Toit MD, Kanchana Than-in-at MSc, Marisa Groenewald MD, Ratchada Cressey PhD, James Nielsen MD, Edmund V Capparelli PharmD, Marc Lallemant MD, Prof Mark F Cotton PhD, Tim R Cressey PhD, PETITE-ABC/3TC-LPVr Study Team
Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates. In this open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and
-
Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data Lancet HIV (IF 12.8) Pub Date : 2024-01-29 Waasila Jassat PhD, Caroline Mudara MSc, Lovelyn Ozougwu MSc, Richard Welch BSc, Tracy Arendse MPH, Maureen Masha MPH, Lucille Blumberg DScMed, Tendesayi Kufa PhD, Adrian Puren PhD, Michelle Groome PhD, Nevashan Govender MSc, Pedro Pisa PhD, Sharlene Govender MPH, Prof Ian Sanne FCP, Heena Brahmbhatt PhD, Lauren Parmley MSPH, Milani Wolmarans BOT, Petro Rousseau PhD, Anthony Selikow BSc, Melissa Burgess
In 2021, the HIV prevalence among South African adults was 18% and more than 2 million people had uncontrolled HIV and, therefore, had increased risk of poor outcomes with SARS-CoV-2 infection. We investigated trends in COVID-19 admissions and factors associated with in-hospital COVID-19 mortality among people living with HIV and people without HIV. In this analysis of national surveillance data, we
-
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies Lancet HIV (IF 12.8) Pub Date : 2024-01-24 Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hessamfar, Peter Reiss, Katharina Kusejko, Michael J Silverberg, Arkaitz Imaz, Ramon Teira, Antonella d'Arminio Monforte, Robert Zangerle, Jodie L Guest, Vasileios Papastamopoulos, Heidi Crane, Timothy R Sterling, Sophie Grabar, Suzanne M Ingle, Jonathan A C Sterne
Background Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America. Methods In this collaborative
-
HIV and people who inject drugs: inequality until death Lancet HIV (IF 12.8) Pub Date : 2024-01-24 Carole Seguin-Devaux
Abstract not available
-
Correction to Lancet HIV 2023; 10: e663–73 Lancet HIV (IF 12.8) Pub Date : 2024-01-22
Abstract not available
-
Closeted life of a Hollywood giant Lancet HIV (IF 12.8) Pub Date : 2024-01-25 Talha Burki
Abstract not available
-
UK emergency department testing for HIV expanded Lancet HIV (IF 12.8) Pub Date : 2024-01-19 Tony Kirby
Abstract not available
-
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies Lancet HIV (IF 12.8) Pub Date : 2024-01-12 Rachel Sacks-Davis PhD, Daniela K van Santen PhD, Anders Boyd PhD, Jim Young PhD, Ashleigh Stewart PhD, Prof Joseph S Doyle PhD, Prof Andri Rauch PhD, Catrina Mugglin PhD, Prof Marina Klein PhD, Prof Marc van der Valk PhD, Colette Smit PhD, Prof Inmaculada Jarrin PhD, Juan Berenguer PhD, Prof Karine Lacombe PhD, Maria-Bernarda Requena MSc, Linda Wittkop PhD, Olivier Leleux PhD, Prof Fabrice Bonnet
Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in incidence of HCV reinfection among people with HIV following the introduction of direct-acting antivirals, and the proportion of all incident cases attributable to reinfection. We pooled individual-level